Related Experiment Video
Updated: May 30, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Targeting oncogenic BRAF in human cancer
Christine A Pratilas1, Feng Xing, David B Solit
1Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Current Topics in Microbiology and Immunology
|August 6, 2011
Summary
Activating BRAF mutations drive cancer by promoting cell proliferation. Targeted inhibitors show promise for treating cancers with these specific BRAF mutations, offering improved efficacy and reduced toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Mitogen Activated Protein Kinase (MAPK) pathway activation is common in human cancers.
- Activating mutations in BRAF and RAS oncogenes frequently drive MAPK pathway activation.
- BRAF V600E mutations occur in approximately 8% of human tumors, particularly melanoma, colon, thyroid, and lung cancers.
Purpose of the Study:
- To investigate the role of BRAF mutations in cancer development.
- To explore the potential of targeted BRAF inhibitors for cancer therapy.
- To evaluate the efficacy and toxicity of BRAF-selective inhibitors.
Main Methods:
- Analysis of BRAF and RAS oncogene mutations in human tumors.
- Assessment of (V600E)BRAF's oncogenic properties, including ERK signaling stimulation, proliferation, and transformation.
- Clinical evaluation of BRAF-selective inhibitors (PLX4032, GSK2118436).
Main Results:
- BRAF mutations, predominantly V600E, are oncogenic drivers in various human cancers.
- (V600E)BRAF promotes cell proliferation and transformation.
- Early clinical trials with BRAF inhibitors demonstrate promising results for specific patient groups.
Conclusions:
- Targeted inhibition of BRAF offers a promising therapeutic strategy for BRAF-mutated cancers.
- BRAF inhibitors may provide greater efficacy and reduced toxicity compared to current systemic therapies.
- The development of BRAF-selective agents holds potential for successful treatment of tumors driven by oncogenic BRAF.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...